COMPANY

Nuvaira

HQ: Minneapolis, MN source · nuvaira.com ↗ · Midwest

Keywords: chronic obstructive pulmonary disease medical device COPD Asthma Targeted Lung Denervation TLD Therapy (IPS SystemTM) IPS System

Location: Minneapolis, MN · source · Oct 14, 2026

Profile checked Oct 10, 2026

Funding and NIH signals

SEC Form D raise Raised $35.76M (Form D filed Mar 4, 2026). SEC Form D 0001461990-26-000003 (Mar 4, 2026)
Evidence (1 event)
- Mar 4, 2026 · SEC Form D 0001461990-26-000003
  Name of Issuer: NUVAIRA, INC.; CIK: 1461990; Address: Minneapolis, MN; Submission type: D; Filing date: 2026-03-04; Industry Group: Other Health Care; Date of First Sale: 2026-02-20; Types of Securities Offered: Equity, Other (Conversion of SAFEs; Conversion of debt); Business combination transaction: false; Total Offering Amount: 63576279; Total Amount Sold: 35764878; Federal exemptions: 06b

Job counts as of Oct 18, 2026. All funding and NIH signals

Feb 24, 2026 Trial start Not phased (device or behavioral study): Evaluating the Safety and Efficacy of dNerva Lung Denervation System in Patients With COPD source ↗
May 23, 2019 Trial start Not phased (device or behavioral study): Evaluation of the Safety and Efficacy of TLD in Patients with COPD source ↗
Dec 22, 2017 Trial start Not phased (device or behavioral study): Evaluating the Safety and Feasibility of TLD for the Treatment of Severe Asthma source ↗
2017-12 Trial start —: Discovery of the Impact of Targeted Lung Denervation (TLD) on the Severe and Very Severe COPD Population source ↗
Aug 4, 2014 Trial start Not phased (device or behavioral study): Targeted Lung Denervation for Patients With Moderate to Severe COPD source ↗
2012-10 Trial start Phase 1: Evaluation of the IPS System for TLD Therapy in Patients With COPD source ↗
2011-10 Trial start Phase 1: Innovative Pulmonary Solutions (IPS) System for Targeted Lung Denervation source ↗

Apr 30, 2028 (ESTIMATED) · Not phased · Evaluating the Safety and Efficacy of dNerva Lung Denervation System in Patients With COPD · NCT07051707

Estimated primary completion per ClinicalTrials.gov. Dates move.

Record	Title	Phase	Status	Start	Primary completion
NCT07051707	Evaluating the Safety and Efficacy of dNerva Lung Denervation System in Patients With COPD	Not phased (device or behavioral study)	Recruiting	Feb 24, 2026	Apr 30, 2028 (estimated)
NCT03639051	Evaluation of the Safety and Efficacy of TLD in Patients with COPD	Not phased (device or behavioral study)	Active, not recruiting	May 23, 2019	Oct 1, 2024 (actual)
NCT02058459	Targeted Lung Denervation for Patients With Moderate to Severe COPD	Not phased (device or behavioral study)	Completed	Aug 4, 2014	Jan 26, 2018 (actual)
NCT02872298	Evaluating the Safety and Feasibility of TLD for the Treatment of Severe Asthma	Not phased (device or behavioral study)	Terminated	Dec 22, 2017	Apr 6, 2020 (actual)
NCT03213080	Discovery of the Impact of Targeted Lung Denervation (TLD) on the Severe and Very Severe COPD Population	Not listed	Withdrawn	2017-12	2021-09 (estimated)
NCT01483534	Innovative Pulmonary Solutions (IPS) System for Targeted Lung Denervation	Phase 1	Completed	2011-10	2013-11 (actual)
NCT01716598	Evaluation of the IPS System for TLD Therapy in Patients With COPD	Phase 1	Completed	2012-10	2014-05 (actual)